Viavi Solutions heads into its April 30 earnings print after the most aggressive price rerating the stock has seen in years — and the analyst community is visibly scrambling to keep up.
The stock closed at $45.53 on Wednesday, a 31% gain over the past month and 5.5% higher on the day alone. That move has now carried the stock clean through several recently raised price targets. After last quarter's results in January triggered a 16% single-day jump and a 20% rally over the following five trading days, momentum has remained firmly in the bulls' hands. Options positioning has turned more cautious at the margin — the put/call ratio hit 0.48, its highest reading of the past year and roughly 1.5 standard deviations above its 20-day average of 0.40 — but that is hedging rather than outright bearishness, consistent with a stock that has moved aggressively and where holders want protection.
The most striking analyst move came just six days ago. B. Riley's Dave Kang doubled his price target in a single step — from $26 to $53 — while maintaining his Buy rating. The target revision captures the scale of the repricing the Street is now trying to process. The mean consensus target sits at $40.43, which the stock has already lapped, leaving the analyst community in a rare position where the current price sits above average street targets. Rosenblatt and Needham had both raised targets earlier in the quarter — to $42 and $36 respectively — and those too now trail the market. The bullish read is straightforward: accelerating 5G network test demand, a growing aerospace and defence presence via Resilient PNT, and operational leverage. Bears point to reorganisation friction in the service enablement segment, competitive pressure in lab testing, and a stock that has re-rated sharply to a P/E above 50x — well ahead of the historical average closer to 22x.
Short interest tells a story of bears retreating rather than advancing. SI has dropped roughly 14% over the past month, easing to 6.3% of the free float from peaks above 8% in mid-April. Borrow conditions remain entirely relaxed — cost to borrow is running below 0.45% and availability is ample — with no meaningful squeeze dynamic in the lending market. The ORTEX short score of 45 sits comfortably in the middle of the range, and availability near its 52-week loosest reflects broad disinterest from the short-selling community despite the sharp run-up.
On the institutional side, T. Rowe Price added nearly two million shares in Q1 and Columbia Management added over two million — both meaningful accumulation against the stock's total float. That institutional buying was happening at prices well below current levels, a detail that adds context to the pace of the re-rating. The earnings report today is therefore less a question of whether demand for Viavi's network test solutions is real, and more a test of whether the company can deliver revenue and margin guidance that justifies a stock price that has already run well past what most analysts were willing to put in print.
See the live data behind this article on ORTEX.
Open VIAV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
